Ratings by Truist Securities (Gregory Renza)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/27/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 8/26/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2026 | Exelixis | EXEL | Maintain | Hold (N/A) |
|
Details | ||
| 8/4/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | Zymeworks | ZYME | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | Exelixis | EXEL | Maintain | Hold (N/A) |
|
Details | ||
| 6/30/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2026 | Exelixis | EXEL | New Coverage | Hold (Buy) |
52.87 (57.58) |
8.91% | Details | |
| 6/9/2026 | Zymeworks | ZYME | New Coverage | Buy (N/A) |
23.93 (26.70) |
11.58% | Details | |
| 6/9/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Buy (N/A) |
232.04 (242.46) |
4.49% | Details | |
| 6/2/2026 | Fulcrum Therapeutics | FULC | Downgrade | Hold (Buy) |
6.92 (3.80) |
-45.09% | Details | |
| 5/27/2026 | Genmab A/S | GMAB | New Coverage | Buy (N/A) |
26.89 (32.33) |
20.23% | Details | |
| 5/27/2026 | Viking Therapeutic | VKTX | New Coverage | Buy (N/A) |
30.80 (32.33) |
4.97% | Details | |
| 5/18/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
145.66 (203.27) |
39.55% | Details | |
| 2/4/2026 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details |
